Françoise Camila Pereira Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Françoise Camila Pereira Santos has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Danielle Glória Souza
Host-Microorganism Interaction Laboratory, Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
1 shared publication - Fernão Castro Braga
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
1 shared publication - Mauro Martins Teixeira
Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Brazil
1 shared publication - Priscilla Rodrigues Valadares Campana
Departament of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, campus Pampulha, Avenida Antônio Carlos 6627, 31.270-901, Belo Horizonte, MG, Brazil
1 shared publication - Rodrigo Maia de Pádua
Department of Pharmaceutical Products Universidade Federal de Minas Gerais Belo Horizonte Brazil
1 shared publication - Rosângela Santos Pereira
Department of Pharmaceutical Products Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos 6627, 31270-901, Belo Horizonte, Brazil
1 shared publication
Latest Publications
- Open Access
Natural Products and Derivatives as Potential Zika virus Inhibitors: A Comprehensive Review
Zika virus (ZIKV) is an arbovirus whose infection in humans can lead to severe outcomes. This article reviews studies reporting the anti-ZIKV activity of natural products (NPs) and derivatives published from 1997 to 2022, which were carried out with NPs obtained from plants (82.4%) or semisynthetic/synthetic derivatives, fungi (3.1%), bacteria (7.6%), animals (1.2%) and marine organisms (1.9%) along with miscellaneous compounds (3.8%). Classes of NPs reported to present anti-ZIKV activity include polyphenols, triterpenes, alkaloids, and steroids, among others. The highest values of the selectivity index, the ratio between cytotoxicity and antiviral activity (SI = CC50/EC50), were reported for epigallocatechin gallate (SI ≥ 25,000) and anisomycin (SI ≥ 11,900) obtained from Streptomyces bacteria, dolastane (SI = 1246) isolated from the marine seaweed Canistrocarpus cervicorni, and the flavonol myricetin (SI ≥ 862). NPs mostly act at the stages of viral adsorption and internalization in addition to presenting virucidal effect. The data demonstrate the potential of NPs for developing new anti-ZIKV agents and highlight the lack of studies addressing their molecular mechanisms of action and pre-clinical studies of efficacy and safety in animal models. To the best of our knowledge, none of the active compounds has been submitted to clinical studies.
Open AccessNatural Products and Derivatives as Potential Zika virus Inhibitors: A Comprehensive Review
Zika virus (ZIKV) is an arbovirus whose infection in humans can lead to severe outcomes. This article reviews studies reporting the anti-ZIKV activity of natural products (NPs) and derivatives published from 1997 to 2022, which were carried out with NPs obtained from plants (82.4%) or semisynthetic/synthetic derivatives, fungi (3.1%), bacteria (7.6%), animals (1.2%) and marine organisms (1.9%) along with miscellaneous compounds (3.8%). Classes of NPs reported to present anti-ZIKV activity include polyphenols, triterpenes, alkaloids, and steroids, among others. The highest values of the selectivity index, the ratio between cytotoxicity and antiviral activity (SI = CC50/EC50), were reported for epigallocatechin gallate (SI ≥ 25,000) and anisomycin (SI ≥ 11,900) obtained from Streptomyces bacteria, dolastane (SI = 1246) isolated from the marine seaweed Canistrocarpus cervicorni, and the flavonol myricetin (SI ≥ 862). NPs mostly act at the stages of viral adsorption and internalization in addition to presenting virucidal effect. The data demonstrate the potential of NPs for developing new anti-ZIKV agents and highlight the lack of studies addressing their molecular mechanisms of action and pre-clinical studies of efficacy and safety in animal models. To the best of our knowledge, none of the active compounds has been submitted to clinical studies.